slides · global inventory
47 Quick Win Big Bet
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,718
Current window 5,371-5,400
Pages 324
Rows per page 30
Loop
5,371-5,400 of 9,718
30
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a specific focus on biomarker-driven patient selection.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
The slide displays a heatmap of 43 patient samples showing ABS scores, signature scores, and cancer diagnoses.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
Includes specific p-values for Blood Mononuclear Cells and references to Fong et al (2020) and Vladimer et al (2022).Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses a combination of donut charts for sample sizes and bar charts for statistical significance, followed by scatter plots to visualize the inverse correlation.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
34
The slide presents two line charts with box plots showing dose-response relationships in lung cancer samples.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
35
The slide presents two key charts: a scatter plot showing the correlation between plasma exposure and target inhibition, and a line chart showing plasma concentration over time.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
36
The slide uses a stylized molecular visualization as a background element.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
38
Includes a biological pathway diagram and a honeycomb diagram for indications.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
39
The slide uses a three-column layout to define the target product profile (TPP) requirements for a CDK7 inhibitor.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
40
The table uses a color-coded heatmap (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
41
Data source: Besnard et al, AACR (2022).Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
42
The slide uses a small multiples approach to show dose-response curves across 10 patient samples, then aggregates them into two groups to highlight differential sensitivity.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
43
The right chart is a waterfall plot showing drug response scores across 53 patient samples, categorized by tumor type and responder status.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
44
The slide shows a hierarchical clustering heatmap of gene expression alongside bar charts comparing experimental vs predicted tDRS values for 30 sample patients.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
45
The slide uses a stylized abstract graphic, likely representing molecular structures or data points.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
46
TPP stands for Target Product Profile.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
47
The slide uses a traffic-light color coding system (green/yellow/red) to visualize performance metrics.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
48
The slide uses a process-flow layout to describe the company's proprietary drug discovery methodology.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
49
The slide uses a high-impact visual of a protein-ligand interaction to establish the product's identity.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
50
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
51
Includes two distinct biological diagrams/illustrations and citations for scientific literature.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
52
The slide uses a three-column layout to define the technical requirements for the drug candidate.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
53
The slide uses a color-coded heatmap (green/yellow/red/grey) to visualize performance against target product profile (TPP) criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
54
The slide uses a linear process flow to describe a drug discovery pipeline.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
55
The chart illustrates a Pareto front analysis in drug discovery, highlighting the selection of compounds that are not necessarily 'optimal' by standard metrics but provide high information value.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
56
Includes statistical significance markers (*) and safety observation regarding body weight.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
57
The slide uses two distinct chart types (dot plot and line chart) to contrast the safety profiles of reversible vs irreversible LSD1 inhibitors.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
58
The chart shows tumour volume over time for various dosing regimens, with statistical significance indicated by ****.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
59
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit